SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark settles up with Merck for Zetia

12 May 2010 Evaluate

Drug-maker Glenmark is set to benefit from the settlement of its patent litigation with Merck on ezetimibe, the cholesterol-modifying drug sold by the latter as Zetia. Zetia is a blockbuster product, with its sales in the US estimated at $1.4 billion.

 

The settlement gives Glenmark a four-and-a-half-month period of exclusive sales that gets shared with Par Pharmaceutical, following a deal on the same drug earlier this month. The settlement with Merck ends the lawsuit involving a challenge by Glenmark – as it sought to launch a generic version of Zetia before the April 2017 expiration of the patent exclusivity on the drug.

 

The agreement will now allow Glenmark to launch its product in the US on December 12, 2016, or earlier under certain circumstances, ahead of the April 25, 2017, expiration of Merck's patent exclusivity for Zetia.

 

Glenmark looks set to get about $150 million when generic Zetia hits the market in 2016, despite the licensing and supply agreement with Par Pharma. Under the existing agreement, Par had paid Glenmark for exclusive rights to market, sell and distribute ezetimibe in the US. The companies will share profits from the sales of the product.

crackcrack

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×